- Home
- ENGN vs TLSI Comparison
ENGN vs TLSI Comparison
Compare ENGN & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- TLSI
- Stock Information
- Founded
- ENGN 1999
- TLSI 2010
- Country
- ENGN Canada
- TLSI United States
- Employees
- ENGN N/A
- TLSI N/A
- Industry
- ENGN
- TLSI Medical Specialities
- Sector
- ENGN
- TLSI Health Care
- Exchange
- ENGN Nasdaq
- TLSI Nasdaq
- Market Cap
- ENGN 191.1M
- TLSI 204.0M
- IPO Year
- ENGN N/A
- TLSI N/A
- Fundamental
- Price
- ENGN $3.83
- TLSI $4.18
- Analyst Decision
- ENGN Buy
- TLSI Strong Buy
- Analyst Count
- ENGN 7
- TLSI 5
- Target Price
- ENGN $23.29
- TLSI $10.90
- AVG Volume (30 Days)
- ENGN 94.6K
- TLSI 39.7K
- Earning Date
- ENGN 09-09-2025
- TLSI 08-12-2025
- Dividend Yield
- ENGN N/A
- TLSI N/A
- EPS Growth
- ENGN N/A
- TLSI N/A
- EPS
- ENGN N/A
- TLSI N/A
- Revenue
- ENGN N/A
- TLSI $32,141,000.00
- Revenue This Year
- ENGN N/A
- TLSI $55.39
- Revenue Next Year
- ENGN N/A
- TLSI $54.89
- P/E Ratio
- ENGN N/A
- TLSI N/A
- Revenue Growth
- ENGN N/A
- TLSI 46.20
- 52 Week Low
- ENGN $2.65
- TLSI $3.50
- 52 Week High
- ENGN $11.00
- TLSI $6.04
- Technical
- Relative Strength Index (RSI)
- ENGN 56.57
- TLSI 32.48
- Support Level
- ENGN $3.45
- TLSI $4.18
- Resistance Level
- ENGN $3.94
- TLSI $4.83
- Average True Range (ATR)
- ENGN 0.27
- TLSI 0.26
- MACD
- ENGN 0.00
- TLSI -0.04
- Stochastic Oscillator
- ENGN 76.06
- TLSI 13.68
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.